$SNSE News

Last published 1mo ago

1mo agoSNSE FTHFaeth Therapeutics - 1773851 - FAETH THERAPEUTICS INCEarnings Call TranscriptsOkay, good morning. Thank you everyone for joining here for the third day of the Morgan Stanley Healthcare Conference. My name is Jason Russell, I'm the Managing Director with the team, and it is a pleasure to be joined
4mo agoSNSE FTHSensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in CancerBusiness Wire— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on
5mo agoSNSESensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on June 1, 2026, the Compensation Committee of Sensei's Board of Directors granted three new employees options to purchase an aggregate of
6mo agoSNSESensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateBusiness WireFirst patient dosed in Phase 1b/2 trial of PIKTOR in HR+/HER2- advanced breast cancer Topline Phase 2 data in patients with advanced endometrial cancer expected in second half 2026 Sensei Biotherapeutics, Inc.
6mo agoGTBP ONCY SNSE VIR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesGlobeNewswireIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly
6mo agoSNSESensei Biotherapeutics Doses First Patient in Phase 1b/2 Trial of PIKTOR in HR+/HER2- Advanced Breast CancerBusiness WirePIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave open Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage
7mo agoSNSESensei Biotherapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceBusiness WireSensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that Company management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16th, 2026 at 12:45 p.m. ET. The live webcast
7mo agoSNSESensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdateBusiness WireFaeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement supports key clinical milestones in endometrial and breast
7mo agoSNSESensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on March 11, 2026, Sensei's Board of Directors granted a new employee an option to purchase 166,435 shares of the Company's common stock in
8mo agoSNSESensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireSensei Biotherapeutics, Inc. (NASDAQ:SNSE) today announced that, effective on February 19, 2026, Sensei's Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893 shares of the
8mo agoSNSESensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private PlacementBusiness WireAcquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer PIKTOR is an investigational
10mo agoSNSEEgle Therapeutics Appoints John Celebi as Chief Executive OfficerGlobeNewswirePARIS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Egle Therapeutics SAS (Egle), a clinical-stage biotechnology company pioneering precision medicines that modulate regulatory T cells (Tregs) to rebalance immune function in
12mo agoSNSESensei Biotherapeutics Reports Third Quarter 2025 Financial ResultsGlobeNewswireBOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients,
1y agoSNSESensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder ValueGlobeNewswireBOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients,
1y agoSNSESensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025GlobeNewswire6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the
1y agoSNSESensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025GlobeNewswireBOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer
1y agoSNSESensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewswireBOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer
1y agoSNSESensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc.
1y agoSNSESensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025GlobeNewswireBOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
1y agoSNSESensei Biotherapeutics Announces 1-for-20 Reverse Stock SplitGlobeNewswireBOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients,
1y agoSNSESensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical ProgressGlobeNewswire- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE
1y agoSNSESensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual ConferenceGlobeNewswireBOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer
1y agoSNSESensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical ProgressGlobeNewswire- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate a
1y agoSNSESensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant TumorsGlobeNewswire– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a
1y agoSNSESensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceGlobeNewswireBOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients,
1y agoSNSESensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesGlobeNewswire- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc.
1y agoSNSESensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare ConferenceGlobeNewswireBOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients,
1y agoSNSESensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash
2y agoSNSESensei Biotherapeutics to Present at Two Upcoming Scientific ConferencesGlobeNewswireBOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today
2y agoSNSESensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy ConferenceGlobeNewswireBOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics to Present at Upcoming ConferencesGlobeNewswireBOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance
2y agoSNSESensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceGlobeNewswireBOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101GlobeNewswire- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on
2y agoSNSESensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsGlobeNewswire- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024
2y agoSNSESensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingGlobeNewswireBOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual ConferenceGlobeNewswireBOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today
2y agoSNSESensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor MicroenvironmentGlobeNewswireBOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics to Participate in the 3rd Annual VISTA SymposiumGlobeNewswireBOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific ConferencesGlobeNewswireBOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business HighlightsGlobeNewswire- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and
2y agoSNSESensei Biotherapeutics to Present at Upcoming ConferencesGlobeNewswireBOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer
2y agoSNSESensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming MilestonesGlobeNewswire- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 - - Strong balance
3y agoSNSESensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewswire- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - - Phase
3y agoSNSESensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual MeetingGlobeNewswire- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose cohorts - - First
3y agoSNSESensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business OfficerGlobeNewswireBOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
3y agoSNSESensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual MeetingGlobeNewswireBOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
3y agoSNSESensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023GlobeNewswireBOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer
3y agoSNSESensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®GlobeNewswire- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety data expected in the
3y agoSNSESensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy ConferenceGlobeNewswire- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile - - Mechanistic mouse data show SNS-101 drives tumor macrophages to adopt an